Meeting
2017 ASCO Annual Meeting
Comparison of chemoradiotherapy (CRT) using carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or gastroesophageal junctional (GEJ) cancer.
Authors
Hao-Wen Sim
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Hao-Wen Sim , Bryan Anthony Chan , Akina Natori , Charles Henry Lim , Di Maria Jiang , Stephanie Moignard , Eric Xueyu Chen , Geoffrey Liu , Gail Elizabeth Darling , Carol Jane Swallow , Savtaj Singh Brar , James D. Brierley , Jolie Ringash , Rebecca Wong , John Kim , Patrik Rogalla , Sara Hafezi-Bakhtiari , Jennifer J. Knox , Raymond Woo-Jun Jang , Elena Elimova
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4053)
DOI
10.1200/JCO.2017.35.15_suppl.4053
Abstract #
4053
Poster Bd #
45
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.
First Author: Karyn A. Goodman
Poster
2018 Gastrointestinal Cancers Symposium
Nonoperative management of locally advanced esophageal and junctional (GEJ) cancers: The University of Rochester experience.
First Author: Rachel Julie David
Poster
2017 Gastrointestinal Cancers Symposium
Cisplatin/5-fluorouracil (CF) versus carboplatin/paclitaxel (CT) chemoradiotherapy (CRT) for locoregionally advanced esophageal cancer (LAEC).
First Author: Michael Marquardt
Poster
2023 ASCO Annual Meeting
Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.
First Author: Jaume Capdevila